CN105640939A - Application of compound separated and extracted from burdock to serving as STAT3 inhibitor - Google Patents
Application of compound separated and extracted from burdock to serving as STAT3 inhibitor Download PDFInfo
- Publication number
- CN105640939A CN105640939A CN201610056773.0A CN201610056773A CN105640939A CN 105640939 A CN105640939 A CN 105640939A CN 201610056773 A CN201610056773 A CN 201610056773A CN 105640939 A CN105640939 A CN 105640939A
- Authority
- CN
- China
- Prior art keywords
- compound
- stat3
- mda
- breast cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
Abstract
The invention belongs to the technical field of medicine, and particularly relates to an application of a compound separated and extracted from burdock to serving as an STAT3 inhibitor. The compound I can be used for a medicine composition for treating triple negative breast cancer. The compound I and docetaxel are combined into a compound preparation for treating triple negative breast cancer for use. Phosphorylation of STAT3 is remarkably inhibited through burdock aglycone in a cell and animal tumor-bearing model, and the burdock aglycone is free of obvious toxic and side effects on other normal tissues. The application has the advantages of being proper in dosage, remarkable in curative effect, clear in action target, small in toxic and side effect and the like, and has the broad anticancer application prospect in clinic. The compound preparation has the low toxic and side effects. As the toxicity of the burdock aglycone is quite low, and the burdock aglycone and the docetaxel are used as a composition, under the condition that the same anticancer curative effect is achieved, the dosage of the docetaxel can be remarkably decreased, and therefore the toxic and side effects brought by the docetaxel can be further reduced.
Description
Technical field
The invention belongs to pharmaceutical technology field, be specifically related to a kind of from Fructus Arctii the compound of separation and Extraction as the purposes of STAT3 inhibitor.
Background technology
Breast carcinoma is the common cancer of serious threat women's health, and the whole world there are about 1400000 women every year and suffers from breast carcinoma, and 450000 die from this disease. In China, breast carcinoma anxious increases with the speed of annual 3%, and age of onset than western countries youth 10-15 year. Three negative breast cancer (triple-negativebreastcancers, TNBC) refer to a kind of Special Types of Breast Cancer that estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor acceptor (HER2) are all negative, account for the 15%-20% of all breast carcinoma. Transfer is the main feature of TNBC, is also the major reason of death, finds the gene relevant to Metastasis in Breast Cancer and carries out effective prevention, for judging prognosis, guiding treatment, improves survival and has great importance.
STAT3 (signaltransducerandactivatoroftranscription-3, STAT3) i.e. cell signalling and activating transcription factor 3, it it is a kind of transcription factor that extracellular signal is transported in core, can be phosphorylated and activate, become STAT3 and pSTAT3 of activation, participate in the growth of cell, propagation, a series of important pathophysiological process such as apoptosis, in normal signal transduction, the activation of STATs is quick and of short duration, STAT3 activates the growth for cell, apoptosis, the regulation and control of cell cycle have important impact, and the regulation and control of Stat3 self is subject in cell multi-signal transduction pathway.
STAT3 is the focus that multiple carcinogenecity tyrosine kinase signal passage such as IL-6/JAK, EGFR, Src collects, kinds of tumor cells and tissue there is excessive activation, such as hematological system tumors such as breast carcinoma, carcinoma of prostate, head and neck cancer, cancer of pancreas, hepatocarcinoma, gastric cancer and leukemia. STAT3 induce after activating above-mentioned with cell proliferation, differentiation, existence, the closely-related key gene of apoptosis unconventionality expression, promote cell proliferation, vicious transformation by all means, block cell apoptosis, shows carcinogenesis, and therefore STAT3 has been considered as a kind of oncogene.
Finding specific bond for the factor played a crucial role in tumor development and suppress the compound of its activity, study mechanism and treatment to tumor all have positive effect.
Arctigenin is a kind of native compound of separation and Extraction from Fructus Arctii, and molecular formula is C21H24O6. Arctigenin to the effect of STAT3, as composition of medicine to three negative breast cancer either with or without controlling breast carcinoma therapeutic effect, all do not report at present. As can be seen here, seek a kind of can as the compound of STAT3 inhibitor so that it is can effectively treat for three negative breast cancer, become the technical barrier that those skilled in the art are urgently to be resolved hurrily.
Summary of the invention
The present invention is to solve above-mentioned technical problem, it is provided that a kind of the compound of separation and Extraction is as the purposes of STAT3 inhibitor from Fructus Arctii, and study mechanism and the treatment of tumor are all had positive effect by it.
In order to reach above-mentioned technique effect, technical scheme includes:
A kind of compound that the structure of separation and Extraction is following from Fructus Arctii (I) purposes in preparing STAT3 inhibitor,
Described compound (I) is arctigenin.
Further, containing the STAT3 inhibitor of compound (I), can be used for reducing the phosphorylation level of STAT3.
Further, containing the STAT3 inhibitor of compound (I), can be used for reducing the phosphorylation level at the 705th tyrosine place of STAT3.
Further, the compound (I) purposes in preparing the pharmaceutical composition for treating three negative breast cancer.
Further, compound (I) and pharmaceutically acceptable adjuvant or complementary composition are mixed with the pharmaceutical composition for treating three negative breast cancer.
Further, compound (I) and Docetaxel composition are for treating the compound preparation of three negative breast cancer.
Further, the dosage form of described pharmaceutical composition and compound preparation for treating three negative breast cancer all includes any one in tablet, powder, granule, capsule, oral liquid, injection or slow releasing agent.
The beneficial effect comprise that
First, arctigenin significantly inhibits the phosphorylation of STAT3 in cell and animal lotus tumor model, to other normal structure without obvious toxic-side effects. Having dosage moderate, evident in efficacy, action target spot is clear and definite, and the advantages such as toxic and side effects is little have extensive anti-cancer applications prospect clinically.
Second, compared with being used alone arctigenin, paclitaxel, compound provided by the invention (I) has significant Synergistic anti-cancer effect for the compound preparation treating three negative breast cancer with Docetaxel composition in treatment three negative breast cancer.
3rd, compound preparation of the present invention has relatively low toxic and side effects. Owing to the toxicity of arctigenin own is very low, arctigenin uses as compositions with Docetaxel, when reaching same anticancer therapeutic, it is possible to significantly reduce the consumption of Docetaxel, so can reduce the toxic and side effects that Docetaxel brings further.
Accompanying drawing explanation
Fig. 1 show arctigenin of the present invention and suppresses STAT3 phosphorylation level detection figure in three negative breast cancer cells MDA-MB-231 cells.
Fig. 2 show arctigenin of the present invention and suppresses STAT3 phosphorylation level detection figure in three negative breast cancer cells MDA-MB-468 cells.
Fig. 3 show caryoplasm separation detection arctigenin of the present invention and suppresses the transcriptional activity figure of STAT3 in MDA-MB-231 cell.
Fig. 4 show caryoplasm separation detection arctigenin of the present invention and suppresses the transcriptional activity figure of STAT3 in MDA-MB-468 cell.
Fig. 5 show the action effect comparison diagram of the collaborative anti-three negative breast cancer MDA-MB-231 cells applied into arctigenin of the present invention and paclitaxel plus.
Fig. 6 show the action effect comparison diagram of the collaborative anti-three negative breast cancer MDA-MB-468 cells applied into arctigenin of the present invention and paclitaxel plus.
Detailed description of the invention
The specific embodiment of the invention is described in detail below in conjunction with concrete accompanying drawing. It should be noted that, what the combination of technical characteristic described in following embodiment or technical characteristic was not construed as isolating, they can be mutually combined thus reaching superior technique effect.
A kind of compound that the structure of separation and Extraction is following from Fructus Arctii (I) purposes in preparing STAT3 inhibitor,
Described compound (I) is arctigenin.
Containing the STAT3 inhibitor of compound (I), can be used for reducing the phosphorylation level of STAT3.
Further, containing the STAT3 inhibitor of compound (I), can be used for reducing the phosphorylation level at the 705th tyrosine place of STAT3.
Compound (I) is used for the purposes treating in the pharmaceutical composition of three negative breast cancer in preparation. Further, compound (I) and pharmaceutically acceptable adjuvant or complementary composition are mixed with the pharmaceutical composition for treating three negative breast cancer.
Compound (I) and Docetaxel composition are for treating the compound preparation of three negative breast cancer.
The dosage form of described pharmaceutical composition and compound preparation for treating three negative breast cancer all includes any one in tablet, powder, granule, capsule, oral liquid, injection or slow releasing agent.
People three negative breast cancer cells system MDA-MB-231 and MDA-MB-468 in following embodiment and all buying from ATCC.
Embodiment 1
Arctigenin suppresses the activation test experience of p-STAT3-tyr (705) in three negative breast cancer cells
Specific implementation method is as follows:
Obtain four kinds of MDA-MB-231 cells processed through the native compound arctigenin (Atn) of variable concentrations as follows: MDA-MB-231 and MDA-MB-468 cell is respectively divided into four groups, one group of MDA-MB-231 (or MDA-MB-468) cell is cultivated 24 hours at 37 DEG C in the L-15 culture medium (addition hyclone (Hyclone) is 10% culture medium obtained to the volumetric concentration of hyclone in L-15 culture medium (Gibco)) containing 10% hyclone, collect MDA-MB-231 cell, obtain the MDA-MB-231 cell that the arctigenin of 0M processes, one group of MDA-MB-231 cell is 4 �� 10-7(in the L-15 culture medium containing 10% hyclone, addition arctigenin is 4 �� 10 to the concentration of arctigenin to M culture medium-7The culture medium that M obtains) in 37 DEG C cultivate 24 hours, collect MDA-MB-231 (or MDA-MB-468) cell, obtain 4 �� 10-7MDA-MB-231 (or MDA-MB-468) cell that the arctigenin of M processes; One group of cell is 8 �� 10-7(in the L-15 culture medium containing 10% hyclone, addition arctigenin is 8 �� 10 to the concentration of arctigenin to M culture medium-7The culture medium that M obtains) in 37 DEG C cultivate 24 hours, collect MDA-MB-231 cell, obtain 8 �� 10-7MDA-MB-231 (or MDA-MB-468) cell that the arctigenin of M processes; One group of MDA-MB-231 (or MDA-MB-468) cell is 1.2 �� 10-6(in the L-15 culture medium containing 10% hyclone, addition arctigenin is 1.2 �� 10 to the concentration of arctigenin to M culture medium-6The culture medium that M obtains) in 37 DEG C cultivate 24 hours, collect MDA-MB-231 (or MDA-MB-468) cell, obtain 1.2 �� 10-6MDA-MB-231 (or MDA-MB-468) cell that the arctigenin of M processes.
Cracking, with RIPA lysate (Sigma), the MDA-MB-231 cell (or MDA-MB-468) that four kinds of native compound arctigenins through variable concentrations process, protein solution is placed in-20 DEG C and preserves or direct Westernblot (western blotting) loading. Molecular size range configuration (8%-12%) polyacrylamide gel according to detection albumen, application of sample rear electrophoresis, the protein transduction after separating according to molecular weight moves on pvdf membrane, and membrane-transferring device is purchased from Bio-Rad company. Pvdf membrane is closed 1 hour with the defatted milk powder of 5% after transferring film, the 4 DEG C of corresponding antibody of night incubation (Anti-p-STAT3-tyr (705), Anti-p-STAT3-ser, Anti-STAT3, Anti-GAPDH), within second day, wash film 1 time with washing the film every 10min of buffer TBST, totally 5 times, two anti-(purchased from the CST) that TBST dilution is corresponding, room temperature 25 DEG C hatches 1.5 hours, the every 10min of TBST washes film 1 time, totally 5 times. ECL test kit, hatches pvdf membrane 2min, darkroom detection exposure.
Experimental result:
As depicted in figs. 1 and 2 it can be seen that arctigenin suppresses the activation of p-STAT3-tyr (705) in three negative breast cancer cells, p-STAT3-ser (727) is not suppressed. Three negative breast cancer cells system MDA-MB-231 and MDA-MB-468 are through arctigenin (Atn, 0,0.4 ��M, 0.8 ��M, 1.2 ��Ms) process after, immunoblot assay detection p-STAT3-tyr (705), p-STAT3-ser (727), STAT3 (antibody is all purchased from CST company), test result indicate that, increase along with concentration, p-STAT3-tyr (705) presents the trend of being decreased obviously, and p-STAT3-ser (727) is then not changed in.
Embodiment 2
The caryoplasm partition method detection arctigenin test experience to the suppression of three negative breast cancer cells transcriptional activities
Obtain four kinds of MDA-MB-231 cells processed through the native compound arctigenin (Atn) of variable concentrations as follows: MDA-MB-231 and MDA-MB-468 cell is respectively divided into four groups, one group of MDA-MB-231 (or MDA-MB-468) cell is cultivated 24 hours at 37 DEG C in the L-15 culture medium (addition hyclone (Hyclone) is 10% culture medium obtained to the volumetric concentration of hyclone in L-15 culture medium (Gibco)) containing 10% hyclone, collect MDA-MB-231 cell, obtain the MDA-MB-231 cell that the arctigenin of 0M processes, one group of MDA-MB-231 cell is 4 �� 10-7(in the L-15 culture medium containing 10% hyclone, addition arctigenin is 4 �� 10 to the concentration of arctigenin to M culture medium-7The culture medium that M obtains) in 37 DEG C cultivate 24 hours, collect MDA-MB-231 (or MDA-MB-468) cell, obtain 4 �� 10-7MDA-MB-231 (or MDA-MB-468) cell that the arctigenin of M processes; One group of cell is 8 �� 10-7(in the L-15 culture medium containing 10% hyclone, addition arctigenin is 8 �� 10 to the concentration of arctigenin to M culture medium-7The culture medium that M obtains) in 37 DEG C cultivate 24 hours, collect MDA-MB-231 cell, obtain 8 �� 10-7MDA-MB-231 (or MDA-MB-468) cell that the arctigenin of M processes; One group of MDA-MB-231 (or MDA-MB-468) cell is 1.2 �� 10-6(in the L-15 culture medium containing 10% hyclone, addition arctigenin is 1.2 �� 10 to the concentration of arctigenin to M culture medium-6The culture medium that M obtains) in 37 DEG C cultivate 24 hours, collect MDA-MB-231 (or MDA-MB-468) cell, obtain 1.2 �� 10-6MDA-MB-231 (or MDA-MB-468) cell that the arctigenin of M processes.
A, the MDA-MB-231 cell (or MDA-MB-468) that four kinds of native compound arctigenins through variable concentrations process is washed twice with pre-cooling PBS;
B, each 10cm ware add 500 �� L pre-cooling PBS, scrape cell, transfer in 1.5mLEP pipe;
C, 4 DEG C, centrifugal 4 minutes of 2000rpm, collect cell;
D, 400 �� LBufferA (10mMHEPES, pH7.9,10mMKCl, 0.1mMEDTA, 1mMDTTandproteaseinhibitors) re-suspended cells, ice bath 10 minutes;
E, add 10 �� L10%NP-40 in cell suspension, acutely shake;
F, 6000rpm, 4 DEG C are centrifuged 4 minutes, and supernatant is cytoplasmic compartment, is precipitated as nuclear fractions;
G, 50 �� L BufferB (20mMHEPES, pH7.9,0.4MNaCl, 1mMEDTA, 1mMDTT+proteaseinhibitors) resuspended precipitation, ice bath 15 minutes, period whirlpool shake several times; 14000rpm, 4 DEG C are centrifuged 5 minutes, and supernatant is nuclear fractions, can in-80 DEG C of preservations. Experiment is in triplicate.
It is shown that as shown in Figure 3 and Figure 4, STAT3 phosphorylation and caryoplasm transfer are subject to the suppression of arctigenin.
Embodiment 3
Arctigenin and the collaborative three negative breast cancer MDA-MB-231 of suppression of paclitaxel and MDA-MB-468 cell detection are tested
After MDA-MB-231 and MDA-MB-468 cell in advance adherent 24 hours, with variable concentrations (0M, 4 �� 10-7M, 8 �� 10-7M) arctigenin (Atn) combines paclitaxel (Tax, 0M, 3 �� 10-8M, 4 �� 10-8M) process MM.1S cell, add MTT detectable after 44 hours and hatch again 4 hours, then measure its light absorption value (OD570) at 570nm by microplate reader. As shown in Figure 5 and Figure 6, arctigenin combines taxol treatment to result, can obviously reduce the OD570 of MDA-MB-231 and MDA-MB-468 cell, shows significant synergy. Arctigenin and paclitaxel are worked in coordination with and are suppressed three negative breast cancer MDA-MB-231 and MDA-MB-468 cell.
Above-mentioned detailed description is illustrating of the possible embodiments for invention, and this embodiment is also not used to limit the scope of the claims of the present invention, and all equivalences without departing from the present invention are implemented or change, and all should be contained in the scope of the claims of the present invention.
It addition, those skilled in the art also can make various amendments, interpolation and replacement in other form and details in the claims in the present invention scope of disclosure and spirit. Certainly, these various amendments, interpolation and replacements etc. made according to present invention spirit change, and all should be included within present invention scope required for protection.
Claims (7)
1. the compound (I) that the structure of separation and Extraction is following from a Fructus Arctii purposes in preparing STAT3 inhibitor,
2. purposes according to claim 1, it is characterised in that containing the STAT3 inhibitor of compound (I), can be used for reducing the phosphorylation level of STAT3.
3. purposes according to claim 2, it is characterised in that containing the STAT3 inhibitor of compound (I), can be used for reducing the phosphorylation level at the 705th tyrosine place of STAT3.
4. purposes according to claim 1, it is characterised in that compound (I) is used for the purposes treating in the pharmaceutical composition of three negative breast cancer in preparation.
5. purposes according to claim 4, it is characterised in that compound (I) and pharmaceutically acceptable adjuvant or complementary composition are mixed with the pharmaceutical composition for treating three negative breast cancer.
6. purposes according to claim 4, it is characterised in that compound (I) and Docetaxel composition are for treating the compound preparation of three negative breast cancer.
7. the purposes according to any one of claim 5 or 6, it is characterized in that, the dosage form of described pharmaceutical composition and compound preparation for treating three negative breast cancer all includes any one in tablet, powder, granule, capsule, oral liquid, injection or slow releasing agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610056773.0A CN105640939A (en) | 2016-01-27 | 2016-01-27 | Application of compound separated and extracted from burdock to serving as STAT3 inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610056773.0A CN105640939A (en) | 2016-01-27 | 2016-01-27 | Application of compound separated and extracted from burdock to serving as STAT3 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105640939A true CN105640939A (en) | 2016-06-08 |
Family
ID=56487990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610056773.0A Pending CN105640939A (en) | 2016-01-27 | 2016-01-27 | Application of compound separated and extracted from burdock to serving as STAT3 inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105640939A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109462A (en) * | 2016-06-24 | 2016-11-16 | 湖北医药学院 | A kind of carcinous inhibitory factor inhibitors of PP2A and preparation method thereof |
| CN108451944A (en) * | 2018-04-09 | 2018-08-28 | 徐军 | A kind of application of STAT3 inhibitor in terms of enhancing NK cells against tumor cells lethality |
| CN109069470A (en) * | 2016-03-21 | 2018-12-21 | 杨宁荪 | Specific Dihydrobenzofuran Lignans are in the purposes for inhibiting breast cancer cell transfer |
| CN109172563A (en) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | A kind of thioxanthene ketone class taxol and STAT3 inhibitor drug combination compositions |
| CN109200052A (en) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | A kind of taxol and Fluorenone class STAT3 inhibitor drug combination compositions |
| CN109223758A (en) * | 2018-10-31 | 2019-01-18 | 南京先进生物材料与过程装备研究院有限公司 | A kind of taxol and fluorenes class STAT3 inhibitor drug combination compositions |
| CN109846888A (en) * | 2018-10-31 | 2019-06-07 | 南京先进生物材料与过程装备研究院有限公司 | A kind of taxol and indoles STAT3 inhibitor drug combination compositions |
| US11059878B2 (en) * | 2016-07-08 | 2021-07-13 | Northwestern University | Therapeutic targeting of SET1B/compass pathway for treating cancers |
-
2016
- 2016-01-27 CN CN201610056773.0A patent/CN105640939A/en active Pending
Non-Patent Citations (6)
| Title |
|---|
| CHIA-JUNG HSIEH,ET AL.: "Arctigenin,a dietary phytoestrogen,induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation", 《FREE RADICAL BIOLOGY AND MEDICINE》 * |
| FEI-FEI ZHOU,ET AL.: "Knockdown of eIF4E suppresses cell growth and migration,enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells", 《MED ONCOL》 * |
| KE HUANG,ET AL.: "Arctigenin Promotes Apoptosis in Ovarian Cancer Cells via the iNOS/NO/STAT3/Survivin Signalling", 《BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY》 * |
| 沈镇宙: "《关爱•自信：沈镇宙教授谈乳腺癌》", 31 October 2014 * |
| 王潞等: "牛蒡子苷及牛蒡子苷元的药理作用研究进展", 《中草药》 * |
| 王静泓等: "牛蒡子苷元通过抑制PI3-K/Akt信号通路诱导肝癌细胞凋亡", 《肿瘤药学》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069470A (en) * | 2016-03-21 | 2018-12-21 | 杨宁荪 | Specific Dihydrobenzofuran Lignans are in the purposes for inhibiting breast cancer cell transfer |
| CN109069470B (en) * | 2016-03-21 | 2022-07-29 | 杨宁荪 | Use of specific benzodihydrofuran lignans for inhibiting breast cancer cell metastasis |
| CN106109462A (en) * | 2016-06-24 | 2016-11-16 | 湖北医药学院 | A kind of carcinous inhibitory factor inhibitors of PP2A and preparation method thereof |
| US11059878B2 (en) * | 2016-07-08 | 2021-07-13 | Northwestern University | Therapeutic targeting of SET1B/compass pathway for treating cancers |
| CN108451944A (en) * | 2018-04-09 | 2018-08-28 | 徐军 | A kind of application of STAT3 inhibitor in terms of enhancing NK cells against tumor cells lethality |
| CN109172563A (en) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | A kind of thioxanthene ketone class taxol and STAT3 inhibitor drug combination compositions |
| CN109200052A (en) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | A kind of taxol and Fluorenone class STAT3 inhibitor drug combination compositions |
| CN109223758A (en) * | 2018-10-31 | 2019-01-18 | 南京先进生物材料与过程装备研究院有限公司 | A kind of taxol and fluorenes class STAT3 inhibitor drug combination compositions |
| CN109846888A (en) * | 2018-10-31 | 2019-06-07 | 南京先进生物材料与过程装备研究院有限公司 | A kind of taxol and indoles STAT3 inhibitor drug combination compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105640939A (en) | Application of compound separated and extracted from burdock to serving as STAT3 inhibitor | |
| Kee et al. | Inhibitory effect of quercetin on colorectal lung metastasis through inducing apoptosis, and suppression of metastatic ability | |
| Hu et al. | Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer | |
| Shen et al. | Magnolol inhibits the growth of non-small cell lung cancer via inhibiting microtubule polymerization | |
| He et al. | Synergistic anticancer effect of curcumin and chemotherapy regimen FP in human gastric cancer MGC‑803 cells | |
| Yang et al. | Celastrus orbiculatus extract triggers apoptosis and autophagy via PI3K/Akt/mTOR inhibition in human colorectal cancer cells | |
| Wang et al. | Curcumin inhibits proliferation and enhances apoptosis in A549 cells by downregulating lncRNA UCA1 | |
| Zhong et al. | Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin‑resistant SKOV3/DDP ovarian cancer cells | |
| Guo et al. | Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells | |
| Thakur et al. | The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition | |
| Lin et al. | Gallic acid suppresses colon cancer proliferation by inhibiting SRC and EGFR phosphorylation | |
| Liu et al. | Suppression of tumor cell proliferation by quinine via the inhibition of the tumor necrosis factor receptor‑associated factor 6‑AKT interaction | |
| Xie et al. | Hispidulin prevents hypoxia-induced epithelial-mesenchymal transition in human colon carcinoma cells | |
| Bian et al. | A pectin-like polysaccharide from Polygala tenuifolia inhibits pancreatic cancer cell growth in vitro and in vivo by inducing apoptosis and suppressing autophagy | |
| Li et al. | Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway | |
| Huang et al. | Gigantol inhibits proliferation and enhances DDP-induced apoptosis in breast-cancer cells by downregulating the PI3K/Akt/mTOR signaling pathway | |
| Wang et al. | Autophagy inhibition enhances the inhibitory effects of ursolic acid on lung cancer cells | |
| Tsering et al. | Triphala suppresses growth and migration of human gastric carcinoma cells in vitro and in a zebrafish xenograft model | |
| Wang et al. | XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy | |
| Liu et al. | Cyanidin curtails renal cell carcinoma tumorigenesis | |
| Yang et al. | Oroxin B selectively induces tumor-suppressive ER stress and concurrently inhibits tumor-adaptive ER stress in B-lymphoma cells for effective anti-lymphoma therapy | |
| Jiang et al. | Role and mechanism of matrine alone and combined with acitretin for HaCaT cells and psoriasis-like murine models | |
| Hirasaka et al. | Dietary supplementation with isoflavones prevents muscle wasting in tumor-bearing mice | |
| Qu et al. | Polysaccharides derived from Balanophora polyandra significantly suppressed the proliferation of ovarian cancer cells through P53‐mediated pathway | |
| Li et al. | Salvianolic acid A inhibits the growth of diffuse large B-cell lymphoma through MAPK pathways |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160608 |
|
| RJ01 | Rejection of invention patent application after publication |